Rizwan Haq
Impact in
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Melanoma and MAPK Pathways 16
- Oncology 30
- Cancer Immunotherapy and Biomarkers 12
- CAR-T cell therapy research 9
- Cutaneous Melanoma Detection and Management 8
- Cancer-related Molecular Pathways 4
- Co-authors
- David E. Fisher (12 shared papers)Jennifer A. Wargo (5 shared papers)Dennie T. Frederick (4 shared papers)Brent W. Zanke (7 shared papers)Hans R. Widlund (2 shared papers)Nicholas Macedo (1 shared paper)David M. Miller (1 shared paper)Howard L. Kaufman (1 shared paper)
- Journals
- Journal of Clinical Oncology (6 papers)Journal for ImmunoTherapy of Cancer (4 papers)Journal of Biological Chemistry (3 papers)Nuclear Physics A (3 papers)Clinical Cancer Research (2 papers)
- Partner nations
- United StatesCanadaJapan
In The Last Decade
Rizwan Haq
58 papers receiving 3.0k citations
Rizwan Haq's Hit Papers
Peers
Comparison fields: 5 of 113
- Oncology 1.2k
- Cancer Research 462
- Immunology 593
- Molecular Biology 1.8k
- Cell Biology 398
Countries citing papers authored by Rizwan Haq
This map shows the geographic impact of Rizwan Haq's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rizwan Haq with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rizwan Haq more than expected).
Fields of papers citing papers by Rizwan Haq
This network shows the impact of papers produced by Rizwan Haq. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rizwan Haq. The network helps show where Rizwan Haq may publish in the future.
Co-authors
The 25 scholars most cited alongside Rizwan Haq, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 60 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF Hit paper breakdown → | 2013 | 610 |
| 2 | A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors Hit paper breakdown → | 2014 | 357 |
| 3 | Clinical landscape of oncolytic virus research in 2020 Hit paper breakdown → | 2020 | 242 |
| 4 | 2013 | 169 | |
| 5 | 2006 | 138 | |
| 6 | Constitutive p38HOG mitogen-activated protein kinase activation induces permanent cell cycle arrest and senescence. | 2002 | 123 |
| 7 | 2019 | 114 | |
| 8 | 2017 | 114 | |
| 9 | 2011 | 112 | |
| 10 | 1985 | 100 | |
| 11 | 2000 | 99 | |
| 12 | 2014 | 77 | |
| 13 | 2012 | 74 | |
| 14 | 2002 | 69 | |
| 15 | 2021 | 47 | |
| 16 | 2019 | 42 | |
| 17 | 2015 | 42 | |
| 18 | Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics | 2022 | 37 |
| 19 | 2017 | 35 | |
| 20 | 1998 | 35 |
About Rizwan Haq
Rizwan Haq is a scholar working on Molecular Biology, Oncology, Immunology, Cell Biology and Nuclear and High Energy Physics, having authored 60 papers that have together received 3.0k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (16 papers), Cancer Immunotherapy and Biomarkers (12 papers), Immunotherapy and Immune Responses (12 papers), CAR-T cell therapy research (9 papers), Cutaneous Melanoma Detection and Management (8 papers), Nuclear physics research studies (8 papers), Ocular Oncology and Treatments (6 papers) and Cancer-related Molecular Pathways (4 papers). The work is most often cited by research in Oncology (1.2k citations), Cancer Research (462 citations), Immunology (593 citations), Molecular Biology (1.8k citations) and Cell Biology (398 citations). Rizwan Haq has collaborated with scholars based in United States, Canada and Japan. Frequent co-authors include David E. Fisher, Jennifer A. Wargo, Dennie T. Frederick, Brent W. Zanke, Hans R. Widlund, Nicholas Macedo, David M. Miller, Howard L. Kaufman, Satoru Yokoyama and Jun S. Song. Their work appears in journals such as Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, Journal of Biological Chemistry, Nuclear Physics A and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.